{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T00:36:06Z","timestamp":1788914166362,"version":"build-2803163510"},"reference-count":39,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,3,1]],"date-time":"2020-03-01T00:00:00Z","timestamp":1583020800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,3,1]],"date-time":"2020-03-01T00:00:00Z","timestamp":1583020800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,1,22]],"date-time":"2020-01-22T00:00:00Z","timestamp":1579651200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100010877","name":"ViiV Healthcare","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010877","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003407","name":"Ministero dell\u2019Istruzione, dell\u2019Universit\u00e0 e della Ricerca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003407","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007054","name":"Meso Scale Diagnostics","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005564","name":"Gilead Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Global Antimicrobial Resistance"],"published-print":{"date-parts":[[2020,3]]},"DOI":"10.1016\/j.jgar.2019.07.015","type":"journal-article","created":{"date-parts":[[2019,7,19]],"date-time":"2019-07-19T20:02:33Z","timestamp":1563566553000},"page":"163-169","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":20,"special_numbering":"C","title":["Evaluation of HIV-1 integrase resistance emergence and evolution in patients treated with integrase inhibitors"],"prefix":"10.1016","volume":"20","author":[{"given":"Rossana","family":"Scutari","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Alteri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4306-2960","authenticated-orcid":false,"given":"Ilaria","family":"Vicenti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Domenico","family":"Di Carlo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6433-506X","authenticated-orcid":false,"given":"Valentina","family":"Zuccaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Incardona","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vanni","family":"Borghi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonia","family":"Bezenchek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimo","family":"Andreoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Antinori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlo Federico","family":"Perno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Cascio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"De Luca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0344-6281","authenticated-orcid":false,"given":"Maurizio","family":"Zazzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Mercedes","family":"Santoro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jgar.2019.07.015_bib0005","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1126\/science.287.5453.646","article-title":"Inhibitors of strand transfer that prevent integration and inhibit HIV-1 replication in cells","volume":"287","author":"Hazuda","year":"2000","journal-title":"Science"},{"key":"10.1016\/j.jgar.2019.07.015_bib0010","unstructured":"Panel on antiretroviral guidelines for adults and adolescents. Guidelines for the use of antiretroviral agents in adults and adolescents living with HIV. Department of health and human services. Last updated December 18, 2019. Available at https:\/\/aidsinfo.nih.gov\/contentfiles\/lvguidelines\/adultandadolescentgl.pdf. Accessed January 6, 2020."},{"key":"10.1016\/j.jgar.2019.07.015_bib0015","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/s12977-017-0360-7","article-title":"HIV drug resistance against strand transfer integrase inhibitors","volume":"14","author":"Anstett","year":"2017","journal-title":"Retrovirol"},{"key":"10.1016\/j.jgar.2019.07.015_bib0020","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1097\/QCO.0000000000000453","article-title":"Dolutegravir resistance mutations: lessons from monotherapy studies","volume":"31","author":"Blanco","year":"2018","journal-title":"Curr Opin Infect Dis"},{"key":"10.1016\/j.jgar.2019.07.015_bib0025","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1016\/S0140-6736(13)61221-0","article-title":"Dolutegravir versus Raltegravir in antiretroviral-experienced, integrase-inhibitor-naive adults with HIV: week 48 results from the randomised, double-blind, non-inferiority SAILING study","volume":"382","author":"Cahn","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.jgar.2019.07.015_bib0030","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1097\/QAD.0000000000001494","article-title":"Emergent drug resistance with integrase strand transfer inhibitor-based regimens","volume":"31","author":"Lepik","year":"2017","journal-title":"AIDS"},{"key":"10.1016\/j.jgar.2019.07.015_bib0035","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1093\/infdis\/jiu051","article-title":"Dolutegravir in antiretroviral-experienced patients with raltegravir- and\/or elvitegravir-resistant HIV-1: 24-week results of the phase III VIKING-3 study","volume":"210","author":"Castagna","year":"2014","journal-title":"J Infect Dis"},{"key":"10.1016\/j.jgar.2019.07.015_bib0040","doi-asserted-by":"crossref","first-page":"7086","DOI":"10.1128\/AAC.01474-16","article-title":"Antiviral activity of bictegravir (GS-9883), a novel potent HIV-1 integrase strand transfer inhibitor with an improved resistance profile","volume":"60","author":"Tsiang","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jgar.2019.07.015_bib0045","doi-asserted-by":"crossref","first-page":"3080","DOI":"10.1093\/jac\/dkv243","article-title":"Integrase inhibitor (INI) genotypic resistance in treatment-naive and raltegravir-experienced patients infected with diverse HIV-1 clades","volume":"70","author":"Doyle","year":"2015","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jgar.2019.07.015_bib0050","doi-asserted-by":"crossref","first-page":"1921","DOI":"10.1093\/jac\/dkv012","article-title":"Non-virological response to a dolutegravir-containing regimen in a patient harbouring a E157Q-mutated virus in the integrase region","volume":"70","author":"Danion","year":"2015","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jgar.2019.07.015_bib0055","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1093\/jac\/dku474","article-title":"G118R and F121Y mutations identified in patients failing raltegravir treatment confer dolutegravir resistance","volume":"70","author":"Munir","year":"2015","journal-title":"J Antimicrob Chemother"},{"issue":"8","key":"10.1016\/j.jgar.2019.07.015_bib0060","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00315-17","article-title":"Impact of HIV-1 integrase L74F and V75I mutations in a clinical isolate on resistance to second-generation integrase strand transfer inhibitors","volume":"61","author":"Hachiya","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jgar.2019.07.015_bib0065","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.antiviral.2018.01.013","article-title":"Novel secondary mutations C56S and G149A confer resistance to HIV-1 integrase strand transfer inhibitors","volume":"152","author":"Yoshinaga","year":"2018","journal-title":"Antiviral Res"},{"key":"10.1016\/j.jgar.2019.07.015_bib0070","first-page":"17","article-title":"Characterization and structural analysis of HIV-1 integrase conservation","volume":"11","author":"Ceccherini-Silberstein","year":"2009","journal-title":"AIDS Rev"},{"key":"10.1016\/j.jgar.2019.07.015_bib0075","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1093\/jac\/dkp423","article-title":"Integrase variability and susceptibility to HIV integrase inhibitors: impact of subtypes, antiretroviral experience and duration of HIV infection","volume":"65","author":"Garrido","year":"2010","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jgar.2019.07.015_bib0080","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1093\/jac\/dks474","article-title":"HIV-1 integrase variability and relationship with drug resistance in antiretroviral-naive and -experienced patients with different HIV-1 subtypes","volume":"68","author":"Reigadas","year":"2013","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jgar.2019.07.015_bib0085","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0181357","article-title":"Collaborative update of a rule-based expert system for HIV-1 genotypic resistance test interpretation","volume":"12","author":"Paredes","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.jgar.2019.07.015_bib0090","first-page":"27","article-title":"State of the art in HIV drug resistance: science and technology knowledge gap","volume":"20","author":"Boucher","year":"2018","journal-title":"AIDS Rev"},{"key":"10.1016\/j.jgar.2019.07.015_bib0095","doi-asserted-by":"crossref","first-page":"1865","DOI":"10.1093\/jac\/dkv029","article-title":"HIV-1 integrase genotyping is reliable and reproducible for routine clinical detection of integrase resistance mutations also in patients with low-level viremia","volume":"70","author":"Armenia","year":"2015","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jgar.2019.07.015_bib0100","first-page":"269","article-title":"Estimation of evolutionary distance between nucleotide sequences","volume":"1","author":"Tajima","year":"1984","journal-title":"Mol Biol Evol"},{"key":"10.1016\/j.jgar.2019.07.015_bib0105","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1002\/sim.4780090710","article-title":"More powerful procedures for multiple significance testing","volume":"9","author":"Hochberg","year":"1990","journal-title":"Stat Med"},{"key":"10.1016\/j.jgar.2019.07.015_bib0110","doi-asserted-by":"crossref","first-page":"2485","DOI":"10.1093\/jac\/dkq350","article-title":"Integrase inhibitors in the treatment of HIV-1 infection","volume":"65","author":"Powderly","year":"2010","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jgar.2019.07.015_bib0115","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1186\/1471-2334-12-368","article-title":"HIV-1 integrase resistance among antiretroviral treatment naive and experienced patients from Northwestern Poland","volume":"12","author":"Parczewski","year":"2012","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.jgar.2019.07.015_bib0120","doi-asserted-by":"crossref","first-page":"2885","DOI":"10.1093\/jac\/dkv202","article-title":"Primary resistance to integrase strand-transfer inhibitors in Europe","volume":"70","author":"Casadell\u00e0","year":"2015","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jgar.2019.07.015_bib0125","doi-asserted-by":"crossref","first-page":"77","DOI":"10.3851\/IMP2780","article-title":"Lack of resistance to integrase inhibitors among antiretroviral-naive subjects with primary HIV-1 infection, 2007\u20132013","volume":"20","author":"Stekler","year":"2015","journal-title":"Antiviral Ther"},{"key":"10.1016\/j.jgar.2019.07.015_bib0130","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.jcv.2017.04.012","article-title":"HIV-1 integrase inhibitor resistance among treatment na\u00efve patients in the West of Scotland","volume":"92","author":"Bradley-Stewart","year":"2017","journal-title":"J Clin Virol"},{"key":"10.1016\/j.jgar.2019.07.015_bib0135","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1089\/aid.2018.0006","article-title":"Prevalence of integrase strand transfer inhibitors resistance mutations in integrase strand transfer inhibitors-naive and -experienced HIV-1 infected patients: a single center experience","volume":"34","author":"De Francesco","year":"2018","journal-title":"AIDS Res Human Retrovir"},{"key":"10.1016\/j.jgar.2019.07.015_bib0140","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1089\/aid.2018.0213","article-title":"Integrase strand transfer inhibitor resistance mutations in antiretroviral therapy-naive and treatment-experienced HIV patients in South Korea","volume":"35","author":"Jeong","year":"2019","journal-title":"AIDS Res Hum Retrovir"},{"key":"10.1016\/j.jgar.2019.07.015_bib0145","doi-asserted-by":"crossref","first-page":"2480","DOI":"10.1093\/jac\/dky211","article-title":"Impact of transmitted HIV-1 drug resistance on the efficacy of first-line antiretroviral therapy with two nucleos(t)ide reverse transcriptase inhibitors plus an integrase inhibitor or a protease inhibitor","volume":"73","author":"Spertilli Raffaelli","year":"2018","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jgar.2019.07.015_bib0150","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1016\/S0140-6736(09)60918-1","article-title":"Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-na\u00efve patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial","volume":"374","author":"Lennox","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.jgar.2019.07.015_bib0155","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1097\/QAD.0b013e32833a608a","article-title":"Substitution of raltegravir for ritonavir-boosted protease inhibitors in HIV-infected patients: the SPIRAL study","volume":"24","author":"Mart\u00ednez","year":"2010","journal-title":"AIDS"},{"key":"10.1016\/j.jgar.2019.07.015_bib0160","doi-asserted-by":"crossref","first-page":"2429","DOI":"10.1016\/S0140-6736(12)60918-0","volume":"379","author":"DeJesus","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.jgar.2019.07.015_bib0165","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/S1473-3099(11)70249-3","article-title":"Efficacy and safety of once daily elvitegravir versus twice daily raltegravir in treatment-experienced patients with HIV-1 receiving a ritonavir-boosted protease inhibitor: randomised, double-blind, phase 3, non-inferiority study","volume":"12","author":"Molina","year":"2012","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.jgar.2019.07.015_bib0170","doi-asserted-by":"crossref","first-page":"2439","DOI":"10.1016\/S0140-6736(12)60917-9","article-title":"Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus co-formulated efavirenz, emtricitabine, and tenofovir for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3 trial, analysis of results after 48 weeks","volume":"379","author":"Sax","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.jgar.2019.07.015_bib0175","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/S0140-6736(12)61853-4","article-title":"Once-daily dolutegravir versus raltegravir in antiretroviral-naive adults with HIV-1 infection: 48 week results from the randomised, double-blind, non-inferiority SPRING-2 study","volume":"381","author":"Raffi","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.jgar.2019.07.015_bib0180","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.1056\/NEJMoa1215541","article-title":"Dolutegravir plus abacavir-lamivudine for the treatment of HIV-1 infection","volume":"369","author":"Walmsley","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jgar.2019.07.015_bib0185","doi-asserted-by":"crossref","first-page":"2222","DOI":"10.1016\/S0140-6736(14)60084-2","article-title":"Once-daily dolutegravir versus darunavir plus ritonavir in antiretroviral-naive adults with HIV-1 infection (FLAMINGO): 48 week results from the randomised open-label phase 3b study","volume":"383","author":"Clotet","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.jgar.2019.07.015_bib0190","doi-asserted-by":"crossref","first-page":"2485","DOI":"10.1093\/jac\/dky198","article-title":"Prevalence and clinical impact of minority resistant variants in patients failing an integrase inhibitor-based regimen by ultra-deep sequencing","volume":"73","author":"Nguyen","year":"2018","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jgar.2019.07.015_bib0195","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1093\/jac\/dku535","article-title":"Cross-resistance to elvitegravir and dolutegravir in 502 patients failing on raltegravir: a French national study of raltegravir-experienced HIV-1-infected patients","volume":"70","author":"Fourati","year":"2015","journal-title":"J Antimicrob Chemother"}],"container-title":["Journal of Global Antimicrobial Resistance"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S221371651930181X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S221371651930181X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T09:53:54Z","timestamp":1761990834000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S221371651930181X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3]]},"references-count":39,"alternative-id":["S221371651930181X"],"URL":"https:\/\/doi.org\/10.1016\/j.jgar.2019.07.015","relation":{},"ISSN":["2213-7165"],"issn-type":[{"value":"2213-7165","type":"print"}],"subject":[],"published":{"date-parts":[[2020,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Evaluation of HIV-1 integrase resistance emergence and evolution in patients treated with integrase inhibitors","name":"articletitle","label":"Article Title"},{"value":"Journal of Global Antimicrobial Resistance","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jgar.2019.07.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 International Society for Antimicrobial Chemotherapy. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}